Low-Density Lipoprotein, Non-High-Density Lipoprotein, and Apolipoprotein B as Targets of Lipid-Lowering Therapy

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial

(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992

The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure

(1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440420033005 · Cited by 3,777

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.

Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162

National Cholesterol Education Program

Lenfant, C. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.1991.00400060019005 · Cited by 1,188

Hypertriglyceridemia as a cardiovascular risk factor

Austin, M. A., Hokanson, J. E., & Edwards, K. L. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00031-9 · Cited by 1,066

National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).

(1994) · Circulation · doi:10.1161/01.cir.89.3.1333 · Cited by 817

Epidemiology as a Guide to Clinical Decisions: The Association between Triglyceride and Coronary Heart Disease

Hulley, S. B., Rosenman, R. H., Bawol, R. D., & Brand, R. J. (1980) · New England Journal of Medicine · doi:10.1056/nejm198006193022503 · Cited by 702

Non–High-Density Lipoprotein Cholesterol Level as a Predictor of Cardiovascular Disease Mortality

Cui, Y. A., Blumenthal, R. S., Flaws, J. A., Whiteman, M. K., LANGENBERG, P. W., Bachorik, P. S., & Bush, T. L. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.11.1413 · Cited by 657

Management of Dyslipidemia in NIDDM

Garg, A., & Grundy, S. M. (1990) · Diabetes Care · doi:10.2337/diacare.13.2.153 · Cited by 260

Fibrinogen and coronary heart disease--what does it mean?

Assmann, G., Schulte, H., Funke, H., & von Eckardstein, A. (1998) · PubMed · Cited by 256

High Plasma Level of Remnant-Like Particles Cholesterol in Familial Combined Hyperlipidemia

Graaf, J. D., van der Vleuten, G. M., ter Avest, E., Dallinga‐Thie, G. M., & Stalenhoef, A. F. H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1973 · Cited by 26

Sinigrin attenuates the progression of atherosclerosis in ApoE−/− mice fed a high-cholesterol diet potentially by inhibiting VCAM-1 expression

Jang, Y. J., Park, B., Lee, H.-W., Park, H. J., Koo, H. J., Kim, B. O., Sohn, E., Um, S. H., & Pyo, S. (2017) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2017.05.006 · Cited by 26

Two adjacent domains (141–150 and 151–160) of apoE covalently linked to a class A amphipathic helical peptide exhibit opposite atherogenic effects

Nayyar, G., Handattu, S. P., Monroe, C. E., Chaddha, M., Datta, G., Mishra, V., Keenum, T. D., Palgunachari, M. N., Garber, D. W., & Anantharamaiah, G. M. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.09.030 · Cited by 25

Effect of omega-3-acid ethyl esters on the steady-state plasma pharmacokinetics of rosuvastatin in healthy adults

Gosai, P., Liu, J., Doyle, R. T., Johnson, J., Carter, R., Sica, D. A., & McKenney, J. M. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560802532640 · Cited by 25

The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups

Catapano, A. L., Toth, P. P., Tomassini, J. E., & Tershakovec, A. M. (2013) · Clinical Lipidology · doi:10.2217/clp.12.88 · Cited by 26

Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care

Harley, C., Gandhi, S. K., Heien, H. C., McDonough, K., & Nelson, S. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.5.669 · Cited by 25

Role of non–high-density lipoprotein cholesterol in prevention of cardiovascular disease: updated evidence from clinical trials

Xydakis, A. M., & Ballantyne, C. M. (2003) · Current Opinion in Cardiology · doi:10.1097/00001573-200311000-00012 · Cited by 25

Metabolic syndrome and risk of acute coronary syndromes in patients younger than 45 years of age

Milionis, H. J., Kalantzi, K. J., Papathanassiou, A., Kosovitsas, A., Doumas, M. T., & Goudevenos, J. A. (2007) · Coronary Artery Disease · doi:10.1097/mca.0b013e328035f8c4 · Cited by 25

Tracking of serum lipid levels from childhood to adulthood: Systematic review and meta-analysis

Stanesby, O., Armstrong, M. K., Otáhal, P., Goode, J. P., Fraser, B. J., Negishi, K., Kidokoro, T., Winzenberg, T. M., Juonala, M., Wu, F., et al. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117482 · Cited by 24

Risk predictive modelling for diabetes and cardiovascular disease

Kengne, A. P., Masconi, K. L., Mbanya, V. N., Lekoubou, A., Echouffo-Tcheugui, J. B., & Matsha, T. E. (2013) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2013.853025 · Cited by 24

Apolipoprotein B, the villain in the drama?

Yu, Q., Zhang, Y., & Xu, C. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.08.037 · Cited by 24

Age-dependence of lipid parameters in the general population and vegetarians

Richter, V., Rassoul, F., Hentschel, B., Kothe, K., Krobara, M., Unger, R. H., Purschwitz, K., Rotzsch, W., Thiery, J., & Muradian, K. K. (2004) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-004-0232-3 · Cited by 23

The association between serum 25-hydroxyvitamin D3 concentration and serum lipids in the rural population of China

Ge, H., Sun, H., Wang, T., Liu, X., Li, X., Yu, F., Han, H., Wang, J., & Li, W. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0603-6 · Cited by 22

Distribuição centrípeta da gordura corporal, sobrepeso e aptidão cardiorrespiratória: associação com sensibilidade insulínica e alterações metabólicas

da Silva, J. L. T., Barbosa, D. S., de Oliveira, J. A., & Guedes, D. P. (2006) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302006000600009 · Cited by 22

Transcriptional Metabolic Inflexibility in Skeletal Muscle Among Individuals With Increasing Insulin Resistance

Jans, A., Sparks, L. M., van Hees, A. M. J., Gjelstad, I. M. F., Tierney, A. C., Risérus, U., Drevon, C. A., Roche, H. M., Schrauwen, P., & Blaak, E. E. (2011) · Obesity · doi:10.1038/oby.2011.149 · Cited by 21

Apolipoprotein B as a long‐term predictor of mortality in type 1 diabetes mellitus: a 15‐year follow up

Stettler, C., Suter, Y., Allemann, S., Zwahlen, M., Christ, E., & Diem, P. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01690.x · Cited by 21

Pattern of dyslipidemia and evaluation of non-HDL cholesterol as a marker of risk factor for cardiovascular disease in type 2 diabetes mellitus.

Pandeya, A., Sharma, M., Regmi, P., Basukala, A., & Lamsal, M. (2012) · PubMed · Cited by 21

Association of Ang-(1–7) and des-Arg9BK as new biomarkers of obesity and cardiometabolic risk factors in adolescents

Fernandes, F. B., Fernandes, A. B., Febba, A. C. S., Leite, A. P. D. O., Leite, C. A., Vitalle, M. S. D. S., Jung, F. F., & Casarini, D. E. (2021) · Hypertension Research · doi:10.1038/s41440-021-00618-0 · Cited by 21

Comparison of Apolipoprotein B and Non-High-Density Lipoprotein Cholesterol for Identifying Coronary Artery Disease Risk Based on Receiver Operating Curve Analysis

Levinson, S. S. (2007) · American Journal of Clinical Pathology · doi:10.1309/22m22rf48px9ut9t · Cited by 21

Non-High-Density Lipoprotein Cholesterol in Patients with Metabolic Syndrome

Huang, J., Parish, R. C., Mansi, I. A., Yu, H., Kennen, E. M., Davis, T. C., & Carden, D. L. (2008) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e318182080a · Cited by 21

Gauging the treatment gap in dyslipidemia: Findings from the 1999-2000 National Health and Nutrition Examination Survey

Klingman, D., Williams, S. A., Benner, J. S., Smith, T. W., Ahn, J., & O’Donnell, J. C. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.09.039 · Cited by 21

Uso de tabaco e perfil lipídico-lipoprotéico plasmático em adolescentes

Guedes, D. P., Guedes, J. E. R. P., Barbosa, D. S., & de Oliveira, J. A. (2007) · Revista da Associação Médica Brasileira · doi:10.1590/s0104-42302007000100021 · Cited by 20

The effect of simvastatin on triglyceride-rich lipoproteins in patients with type 2 diabetic dyslipidemia: a SILHOUETTE Trial Sub-study

Miller, M. J., Dobs, A. S., Yuan, Z., Battisti, W. P., & Palmisano, J. J. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x80521 · Cited by 20

Rosuvastatin reduces intima-media thickness in hypercholesterolemic subjects with asymptomatic carotid artery disease: the Asymptomatic Carotid Atherosclerotic Disease in Manfredonia (ACADIM) Study

Riccioni, G., Bazzano, L., Bucciarelli, T., Mancini, B., di Ilio, E., & D’Orazio, N. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.14.2403 · Cited by 20

Longitudinal association between an overall diet quality index and latent profiles of cardiovascular risk factors: results from a population based 13-year follow up cohort study

Nouri, F., Sadeghi, M., Mohammadifard, N., Roohafza, H., Feizi, A., & Sarrafzadegan, N. (2021) · Nutrition & Metabolism · doi:10.1186/s12986-021-00560-5 · Cited by 19

Advanced Lipoprotein Testing: Recommendations Based on Current Evidence

Lau, J. F., & Smith, D. A. (2009) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.11.008 · Cited by 19

Obesity and Body Fat Classification in the Metabolic Syndrome: Impact on Cardiometabolic Risk Metabotype

Phillips, C. M., Tierney, A. C., Pérez‐Martínez, P., Defoort, C., Blaak, E. E., Gjelstad, I. M. F., López‐Miranda, J., Kieć-Klimczak, M., Malczewska-Malec, M., Drevon, C. A., et al. (2012) · Obesity · doi:10.1038/oby.2012.188 · Cited by 19

The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?

Rizzo, M., Christ, E., Rini, G. B., Spinas, G. A., & Berneis, K. K. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.13.2295 · Cited by 19

Emerging antidyslipidemic drugs

Pollex, R. L., JOY, T. R., & Hegele, R. A. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.13.2.363 · Cited by 19

Association between ESR1 and ESR2 gene polymorphisms and hyperlipidemia in Chinese Han postmenopausal women

Zhao, T., Zhang, D., Liu, Y., Zhou, D., Chen, Z., Yang, Y., Li, S., Yu, L., Zhang, Z., Feng, G., et al. (2009) · Journal of Human Genetics · doi:10.1038/jhg.2009.122 · Cited by 19

Celastrus orbiculatus Thunb. Decreases Athero‐Susceptibility in Lipoproteins and the Aorta of Guinea Pigs Fed High Fat Diet

Zhang, Y., Si, Y., Yao, S., Yang, N., Song, G., Sang, H., Zu, D., Xu, X., Wang, J., & Qin, S. (2013) · Lipids · doi:10.1007/s11745-013-3773-7 · Cited by 18

Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome

Robinson, J. G., Ballantyne, C. M., Hsueh, W. A., Rosen, J. B., Lin, J., Shah, A. K., Tomassini, J. E., Lowe, R. S., & Tershakovec, A. M. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.03.007 · Cited by 18

Management of Dyslipidemia in Patients with Metabolic Syndrome

Cziraky, M. J. (2004) · Journal of the American Pharmacists Association · doi:10.1331/1544345041475643 · Cited by 18

The IL-10-1082 (rs1800896) G allele is associated with a decreased risk of developing premature coronary artery disease and some IL-10 polymorphisms were associated with clinical and metabolic parameters. The GEA study

Posadas‐Sánchez, R., Ángeles-Martínez, J., Pérez‐Hernández, N., Rodrı́guez-Pérez, J. M., López-Bautista, F., Flores-Domı́nguez, C., Fragoso, J. M., Posadas‐Romero, C., & Vargas‐Alarcón, G. (2018) · Cytokine · doi:10.1016/j.cyto.2018.02.028 · Cited by 18

Achieving greater reductions in cardiovascular risk: lessons from statin therapy on risk measures and risk reduction

Ballantyne, C. M. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.04.025 · Cited by 18

Long-Term Efficacy of Adding Fenofibric Acid to Moderate-Dose Statin Therapy in Patients with Persistent Elevated Triglycerides

Ballantyne, C. M., Jones, P. H., Kelly, M. T., Setze, C. M., Lele, A., Thakker, K. M., & Stolzenbach, J. C. (2011) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-011-6280-1 · Cited by 16

Effects of oestrogen receptor‐active compounds on lipid metabolism

Gilchrist, S. C., & Herrington, D. M. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00412.x · Cited by 16

Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non–HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein

Davidson, M. H., Abate, N. I., Ballantyne, C. M., Catapano, A. L., Xu, X., Lin, J., Rosenberg, E., & Tershakovec, A. M. (2008) · Journal of clinical lipidology · doi:10.1016/j.jacl.2008.10.003 · Cited by 16

Non-high density lipoprotein cholesterol versus low density lipoprotein cholesterol as a discriminating factor for myocardial infarction

Sigdel, M., Yadav, B. K., Gyawali, P., Regmi, P., Baral, S., Regmi, S. R., & Jha, B. (2012) · BMC Research Notes · doi:10.1186/1756-0500-5-640 · Cited by 16

Interplay between proteins and metabolic syndrome–A review

Miglani, N., & Bains, K. (2015) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2014.938259 · Cited by 17

Non–high-density lipoprotein cholesterol target achievement in patients on lipid-lowering drugs and stratified by triglyceride levels in the Arabian Gulf

Al-Hashmi, K., Al-Zakwani, I. S., Almahmeed, W. A., Arafah, M., Al-Hinai, A. T., Shehab, A. M., Tamimi, O. A., Alawadhi, M., Herz, S. A., Anazi, F. A., et al. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.12.021 · Cited by 16

Editorial: “Lean” NAFLD: Metabolic Obesity with Normal BMI… Is It in the Genes?

Argo, C. K., & Henry, Z. H. (2017) · The American Journal of Gastroenterology · doi:10.1038/ajg.2016.527 · Cited by 16

C-reactive protein 1059G/C gene polymorphism, C-reactive protein levels and acute myocardial infarction

Ghattas, M. H., Abo–Elmatty, D. M., & El-Eraky, A. Z. (2012) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e3283577170 · Cited by 15

Non–High-Density Lipoprotein Cholesterol and Guidelines for Cholesterol Lowering in Recent History

Levinson, S. S. (2019) · Laboratory Medicine · doi:10.1093/labmed/lmz032 · Cited by 15

A real time non-invasive cholesterol monitoring system

Umar, U., Syarif, S., Nurtanio, I., & Indrabayu, I. (2020) · MATEC Web of Conferences · doi:10.1051/matecconf/202033106005 · Cited by 15

Optimal Medical Management in Patients with Renovascular Hypertension

Balafa, O. C., Kalaitzidis, R., & Siamopoulos, K. C. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0011-x · Cited by 15

Lipid Screening in HIV-Infected Veterans

Korthuis, P. T., Asch, S. M., Anaya, H. D., Morgenstern, H., Goetz, M. B., Yano, E. M., Rubenstein, L. V., Lee, M. L., & Bozzette, S. A. (2004) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200403010-00005 · Cited by 15

Changes in Lipoprotein Particle Number With Ezetimibe/Simvastatin Coadministered With Extended‐Release Niacin in Hyperlipidemic Patients

Le, N., Jin, R., Tomassini, J. E., Tershakovec, A. M., Neff, D., & Wilson, P. W. F. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000037 · Cited by 14

Health behavior and perceptions among African American women with metabolic syndrome

Malayala, S. V., & Raza, A. (2016) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.3402/jchimp.v6.30559 · Cited by 14

The effects of nattokinase supplementation on collagen–epinephrine closure time, prothrombin time and activated partial thromboplastin time in nondiabetic and hypercholesterolemic subjects

Yoo, H. J., Kim, M., Kim, M., Lee, A., Jin, C., Lee, S. P., Kim, T. S., Lee, S., & Lee, J. H. (2019) · Food & Function · doi:10.1039/c8fo02324g · Cited by 14

Treatment of the Dyslipidemia of Insulin Resistance

Smith, D. A. (2007) · Medical Clinics of North America · doi:10.1016/j.mcna.2007.06.008 · Cited by 14

Therapeutic lipid target achievements among high and highest risk patients: results from the CEPHEUS study in the Arabian Gulf

Al‐Rasadi, K., Al-Zakwani, I. S., Almahmeed, W. A., Arafah, M., Al-Hinai, A. T., Shehab, A. M., Tamimi, O. A., & Alawadhi, M. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.965774 · Cited by 14

Rosiglitazone plus metformin: combination therapy for Type 2 diabetes

Prato, S. D., & Volpe, L. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.6.1411 · Cited by 14

Circulating adipokines and insulin resistance in subjects with combined cardiac and metabolic syndrome X

Liang, K., Lee, W., Lee, W.-L., Liao, Y., Wang, K., Lee, I., Wang, J., & Sheu, W. H. (2015) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-015-0078-4 · Cited by 13

Remnant lipoprotein size distribution profiling via dynamic light scattering analysis

Chandra, R., Mellis, B., Garza, K., Hameed, S. A., Jurica, J. M., Hernandez, A. V., Nguyen, M. N., & Mittal, C. K. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.08.012 · Cited by 13

The Incremental Value of Lipids and Inflammatory Biomarkers in Determining Residual Cardiovascular Risk

Mangalmurti, S. S., & Davidson, M. H. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0190-3 · Cited by 13

Epicardial adipose tissue thickness and plasma homocysteine in patients with metabolic syndrome and normal coronary arteries

Balcıoğlu, A. S., Durakoğlugil, M. E., Çiçek, D., Bal, U. A., Boyacı, B., & Müderrisoğlu, H. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-62 · Cited by 13

Sustained postprandial decrease in plasma levels of LDL cholesterol in patients with type‐2 diabetes mellitus

Lund, S. S., Petersen, M., Frandsen, M., Smidt, U., Parving, H. ‐., Vaag, A. A., & Jensen, T. (2008) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510801995736 · Cited by 13

Calculated low-density lipoprotein cholesterol remains a viable and important test for screening and targeting therapy

Abudu, N., & Levinson, S. S. (2007) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2007.291 · Cited by 13

The atherogenic and metabolic impact of non-HDL cholesterol versus other lipid sub-components among non-diabetic and diabetic Saudis

Al‐Daghri, N. M., Al-Attas, O. S., & Al-Rubeaan, K. A. (2007) · Lipids in Health and Disease · doi:10.1186/1476-511x-6-9 · Cited by 13

Lipoprotein and apolipoprotein ratios in the VYTAL trial of ezetimibe/simvastatin compared with atorvastatin in type 2 diabetes

Guyton, J. R., Goldberg, R. B., Mazzone, T., Weinstock, R. S., Polis, A. B., Rosenberg, E., & Tershakovec, A. M. (2008) · Journal of clinical lipidology · doi:10.1016/j.jacl.2007.12.004 · Cited by 13

JTT-705: is there still future for a CETP inhibitor after torcetrapib?

Rennings, A. J. M., & Stalenhoef, A. F. H. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.10.1589 · Cited by 13

Renal impairment is one of appropriate predictors of future diabetic peripheral neuropathy: a hospital-based 6-year follow-up study

Wang, C.-S., Pai, Y., Lin, C., Lee, I., & Chang, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-09333-3 · Cited by 14

Apolipoprotein B is a better marker than non-HDL-cholesterol for the metabolic syndrome in Koreans

Han, J. H., Park, H. S., Kim, J., & Kim, S. M. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.05.021 · Cited by 12

Importance of measuring non-HDL cholesterol in type 2 diabetes patients.

Ram, N., Ahmed, B., Hashmi, F. A., & Jabbar, A. (2014) · PubMed · Cited by 12

Global Risk Management in Patients with Type 2 Diabetes Mellitus

Davidson, M. H. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.005 · Cited by 12

Hypocholesterolemic effects of diets containing different levels of kishk as a dried fermented milk–whole wheat mixture in experimental rats

Ali, R. F. M. (2016) · Journal of Ethnic Foods · doi:10.1016/j.jef.2016.01.009 · Cited by 12

Clinical evaluation of the efficacy of a combination of zanjabeel (Zingiber officinale) and amla (Emblica officinalis) in hyperlipidaemia.

Kamal, R., & Aleem, S. (2009) · Indian Journal of Traditional Knowledge · Cited by 12

A Comparative Study of Serum Uric Acid levels and Lipid Ratios in Coronary Artery Disease Patients

Sathiya, R., Amirtha, G. B., Velu, V. K., Niranjan, G., Srinivasan, A. R., Ramesh, R., Babu, M. S., & Saha, S. (2014) · International Journal of Biomedical Science · doi:10.59566/ijbs.2014.10124 · Cited by 12

Chapter 8 Atherogenic Lipoprotein Subprofiling

Ellington, A. A., & Kullo, I. J. (2008) · Advances in clinical chemistry · doi:10.1016/s0065-2423(08)00408-3 · Cited by 12

Non‐High‐Density Lipoprotein Cholesterol: Why Lower Is Better

Garg, R., Vasamreddy, C. R., & Blumenthal, R. S. (2005) · Preventive Cardiology · doi:10.1111/j.1520-037x.2005.4077.x · Cited by 12

Decreased perivascular CGRP-containing nerves in Otsuka Long–Evans Tokushima Fatty rats with insulin resistance and hypertension

Takatori, S., Fujiwara, H., Zamami, Y., Hashikawa‐Hobara, N., & Kawasaki, H. (2013) · Hypertension Research · doi:10.1038/hr.2013.151 · Cited by 11

How low should we target the LDL goal to improve survival for acute coronary syndrome patients in Hong Kong?

Lee, V. W. Y., Chau, R. Y., Cheung, H. Y., Yu, C., Lam, Y. Y., & Yan, B. P. (2015) · BMC Cardiovascular Disorders · doi:10.1186/s12872-015-0117-y · Cited by 11

Quantitative and functional characteristics of endothelial progenitor cells in newly diagnosed hypertensive patients

Skrzypkowska, M. W., Myśliwska, J. M., Słomiński, B., Siebert, J., Gutknecht, P. G., & Ryba-Stanisławowska, M. E. (2014) · Journal of Human Hypertension · doi:10.1038/jhh.2014.85 · Cited by 11

Anti-hyperlipidemic activity of spider brake ( Pteris multifida ) with rats fed a high cholesterol diet

Wang, T., Lin, C., Lee, H.-I., Yang, C., & Yang, C. (2009) · Pharmaceutical Biology · doi:10.3109/13880200903085458 · Cited by 11

Colesterol não-HDL em escolares de 7 a 17 anos de idade em um município brasileiro

Seki, M. O., Matsuo, T., & Seki, M. (2007) · Revista Panamericana de Salud Pública · doi:10.1590/s1020-49892007000400006 · Cited by 11

Cholesterol and Triglyceride Concentrations in Lipoproteins as Related to Carotid Intima-Media Thickness

Takahashi, R., Taguchi, N., Suzuki, M., Cheng, X. W., Numaguchi, Y., Tsukamoto, H., Ikeda, N., Murohara, T., & Okumura, K. (2012) · International Heart Journal · doi:10.1536/ihj.53.29 · Cited by 10

LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study

OLSSON, A. G., Lindahl, C., Holme, I., Fayyad, R. S., Færgeman, O., Kastelein, J. J. P., Tikkanen, M. J., Larsen, M. L., Pedersen, T. R., & (on behalf of the Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group) (2011) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/1741826710389391 · Cited by 10

Predictive value of serum apolipoprotein B/apolipoprotein A-I ratio in metabolic syndrome risk: a Chinese cohort study

Chou, Y., Kuan, J.-C., Bai, C., Yang, T., Chou, W.-Y., Hsieh, P.-C., You, S., Hwang, L., Chen, C.-H., Wei, C., et al. (2014) · Endocrine · doi:10.1007/s12020-014-0447-z · Cited by 10

Apolipoproteínas B e A-I: fatores de risco cardiovascular?

Forti, N. A., & Diament, J. (2007) · Revista da Associação Médica Brasileira · doi:10.1590/s0104-42302007000300029 · Cited by 10

Hypercholesterolemia and hypertriglyceridemia—greatest cardiac risk in subjects with high apoB/apoA-I levels

Walldius, G., AASTVEIT, A. H., & Jungner, I. (2004) · International Congress Series · doi:10.1016/j.ics.2003.12.033 · Cited by 10

Cardiovascular Disease in Racial and Ethnic Minorities

Ferdinand, K. C., & Armani, A. M. (2010) · Humana Press eBooks · doi:10.1007/978-1-59745-410-0 · Cited by 10

Fasting time and lipid parameters: association with hepatic steatosis — data from a random population sample

Gruchot, M., Graeter, T., Oeztuerk, S., Haenle, M. M., Köenig, W., Imhof, A., Boehm, B. O., Mason, R. A., Kratzer, W., Akinli, A. S., et al. (2014) · Lipids in Health and Disease · doi:10.1186/1476-511x-13-18 · Cited by 9

Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non–HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes

Weinstock, R. S., Goldberg, R. B., Guyton, J. R., Mazzone, T., Polis, A. B., Tomassini, J. E., Lin, J., Shah, A. K., & Tershakovec, A. M. (2008) · Journal of clinical lipidology · doi:10.1016/j.jacl.2008.01.001 · Cited by 9

Hypertriglyceridemia and Cardiovascular Outcomes

Malhotra, G., Sethi, A., & Arora, R. R. (2014) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000116 · Cited by 9

Non-HDL Cholesterol And LDL-C/HDL-C Ratio In Type II Diabetic Patients

Indumati, V., Patil, V. S., Krishnaswamy, D., Satishkumar, D., Viswanathan, V., Mahesh, S., & Rajeshwari, V. A. (2011) · International Journal of Pharma and Bio Sciences · Cited by 9

Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein

Kappelle, P. J. W. H., Zwang, L., Huisman, M. V., Banga, J. D., Sluiter, W. J., Dallinga‐Thie, G. M., & Dullaart, R. P. F. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903023866 · Cited by 9

Software as a Service for the Genomic Prediction of Complex DiseasesPreprint

Bolli, A., Domenico, P. D., & Bottà, G. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/763722 · Cited by 9

Obesity without metabolic disorder and silent brain infarcts in a neurologically healthy population

Nam, K., Kwon, H., Jeong, H., Park, J.-H., Kwon, H., & Jeong, S. (2019) · International Journal of Obesity · doi:10.1038/s41366-019-0372-6 · Cited by 8

The rs12617336 and rs17574 Dipeptidyl Peptidase-4 Polymorphisms Are Associated With Hypoalphalipoproteinemia and Dipeptidyl Peptidase-4 Serum Levels: A Case-Control Study of the Genetics of Atherosclerotic Disease (GEA) Cohort

Vargas‐Alarcón, G., González-Salazar, M. D. C., Vázquez-Vázquez, C., Hernández-Díazcouder, A., Sánchez‐Muñoz, F., Reyes-Barrera, J., Críales-Vera, S., Sánchez-Guerra, M., Osorio-Yáñez, C., & Posadas‐Sánchez, R. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.592646 · Cited by 8

Incidence and Predictors of Chronic Kidney Disease among Diabetes Mellitus Patients: A Retrospective Follow-Up Study at a Tertiary Health-Care Setting of Ethiopia

Debele, G. R., Hajure, M., Wolde, H. F., & Yenit, M. K. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s335572 · Cited by 8

The Achievement of Non-high-density Lipoprotein Cholesterol Target in Patients with Very High Atherosclerotic Cardiovascular Disease Risk Stratified by Triglyceride Levels Despite Statin-controlled Low-density Lipoprotein Cholesterol

Al-Sabti, H. A., Al-Hinai, A. T., Al-Zakwani, I. S., Al-Hashmi, K., Almahmeed, W. A., Arafah, M., Shehab, A. M., Tamimi, O. A., Alawadhi, M., & Herz, S. A. (2022) · Oman Medical Journal · doi:10.5001/omj.2022.79 · Cited by 8

Efficacy and safety of ezetimibe plus atorvastatin therapy

Foody, J. M., Toth, P. P., Tershakovec, A. M., Musliner, T., Tomassini, J. E., Lowe, R. S., Neff, D., & Davis, H. R. (2014) · Clinical Lipidology · doi:10.2217/clp.14.36 · Cited by 8

The association between serum apolipoprotein A-I and apolipoprotein B and the severity of angiographical coronary artery disease.

Ansari, M. H. K., Rasmi, Y., Rahimipour, A., & Jafarzadeh, M. (2009) · PubMed · Cited by 8

Emerging drugs in peripheral arterial disease

Tulsyan, N., Ouriel, K. M., & Kashyap, V. S. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.1.75 · Cited by 8

Comparison of apolipoprotein B and plasma lipids as targets for lipid lowering treatment

Vaverková, H., Frohlich, J. J., Jackuliaková, D., & Novotný, D. (2005) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2005.02.012 · Cited by 8

Serum Lipoprotein(a) Levels in Patients with Atherosclerotic Peripheral Vascular Disease in Hospital Kuala Lumpur

Hakim, N., Hafizan, M. T., Baizurah, M. H., & Zainal, A. A. (2008) · Asian Journal of Surgery · doi:10.1016/s1015-9584(08)60048-2 · Cited by 7

Evidence that Low Density Lipoprotein Is the Primary Cause of Atherosclerotic Cardiovascular Disease: A Bradford-Hill Approach

Schade, D. S., Helitzer, D., & Eaton, P. (2017) · World Journal of Cardiovascular Diseases · doi:10.4236/wjcd.2017.79025 · Cited by 7

Feasibility of postprandial optical scattering of lipoproteins in blood as an optical marker of cardiovascular disease risk: modeling and experimental validation

Pilvar, A., Smith, D. W., Plutzky, J., & Roblyer, D. M. (2023) · Journal of Biomedical Optics · doi:10.1117/1.jbo.28.6.065002 · Cited by 7

Rosuvastatin Enhances the Catabolism of LDL apoB‐100 in Subjects with Combined Hyperlipidemia in a Dose Dependent Manner

Le, N., Diffenderfer, M. R., Thongtang, N., Ooi, E. M. M., Barrett, P. H. R., Horvath, K. V., Dolnikowski, G. G., Asztalos, B. F., Schaefer, E. J., & Brown, W. V. (2015) · Lipids · doi:10.1007/s11745-015-4005-0 · Cited by 7

LDL、非-HDL及apoB是降脂治疗的靶标

余国膺 (2003) · South China Journal of Cardiovascular Diseases

Research digest: new insights into established risk pathways

Preiss, D., & Sattar, N. A. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30091-9

The role of non-LDL:non-HDL particles in atherosclerosis

Segrest, J. P. (2002) · Current Diabetes Reports · doi:10.1007/s11892-002-0096-0 · Cited by 26

Low-density lipoprotein, non high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation

Grundy, S. M., Lipoprotein, L.-D., Lipoprotein, N.-H.-D., & As, A. B. (2015)

An increased number of very-low-density lipoprotein particles is strongly associated with coronary heart disease in Japanese men, independently of intermediate-density lipoprotein or low-density lipoprotein

Koba, S., Hirano, T., Sakaue, T., Takeuchi, H. T., Adachi, M., & Katagiri, T. (2002) · Coronary Artery Disease · doi:10.1097/00019501-200208000-00002 · Cited by 23